CSPC Pharmaceutical Group Limited
1093Company Overview
CSPC Pharmaceutical Group Co., Ltd. (“CSPC Group”) has a leading position in China's pharmaceutical industry. The company was listed on the main board of the Hong Kong Stock Exchange in 1994. It is one of the well-known pharmaceutical listed companies in Hong Kong, China. It is currently one of the Hang Seng Composite Index, Hang Seng Hong Kong Chinese Enterprises Index, and Hang Seng Mainland China's 100 constituent stocks. CSPC Group has three business segments: Innovative Pharmaceuticals, Generic Pharmaceuticals and APIs, and is mainly engaged in the development, production and sale of pharmaceuticals and related products. Proprietary pharmaceutical products mainly include antibiotics, cardiovascular drugs, antipyretic and analgesic drugs, digestive drugs, anti-tumor drugs, and proprietary Chinese medicines. Among them, “Enbip,” “Oulainine,” “Genning,” “Domesin,” “Jinyuli,” and “Nolinine” are innovative pharmaceutical products that sell well in China. API products mainly include antibiotics, vitamin C and caffeine series. The main production base of the CSPC Group is located in Shijiazhuang, Hebei, China. After evaluation by the World Brand Laboratory, one of the top five global brand valuation agencies, the “Shijiao” brand has been selected as “China's 500 Most Valuable Brands” 11 times in a row since 2004. In terms of fulfilling its social responsibilities, CSPC Group has always taken the lead and has always enthusiastically supported social welfare undertakings. In activities such as SARS, the Indonesian tsunami, the Wenchuan earthquake, the Yushu earthquake, medical treatment and volunteer service for seriously ill children, etc. CSPC Group continues to give back to society with practical things.
Shariah Compliance Benchmarks:
- Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
- Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
This stock meets all Shariah compliance criteria according to AAOIFI standards.
| Name | CSPC Pharmaceutical Group Limited |
| Ticker | 1093 |
| Main Business | Drug Manufacturers—General |
| Type | Common Stock |
| Industry | Drug Manufacturers—General |
| Country | HK |
| Market Cap | $10.83 B |
Shariah Analysis Breakdown
| Revenue Segment | Value ($M) | Non-Compliant ($M) | Reason |
|---|---|---|---|
| Finished drugs | $24,520.1 | $0.0 | - |
| Vitamin C | $2,533.4 | $0.0 | - |
| Antibiotics and others | $2,212.6 | $0.0 | - |
| Functional food and others | $2,046.1 | $0.0 | - |
| Other income | $603.8 | $242.5 | Interest income |
| Other gains or losses, net | $291.4 | $219.0 | Financial assets and forex gain |
| Share of results of joint ventures | $27.1 | $0.0 | - |
| Gains on deemed disposal of partial interest in an associate and a joint venture | $48.1 | $0.0 | - |
| Total | $32,282.6 | $461.6 | 1.43% (passed) |
| Liability Item | Value ($M) | % of Market Cap |
|---|---|---|
| bank loans and overdrafts | $63,056,022.4 | 0.58% |
| notes payable | $58,210,084.0 | 0.54% |
| Total Interest-Bearing Debt | $121,266,106.4 | 1.12% |
| Market Capitalization | $10,834,153,846.2 | 100.00% |
| Compliance Status | Threshold: 33% | passed |